دورية أكاديمية
أعرض في EDS

Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.

التفاصيل البيبلوغرافية
العنوان: Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
المؤلفون: Schoettler ML; Department Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia., Carreras E; Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Barcelona, Catalunya, Spain., Cho B; Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, Seoul, Korea., Dandoy CE; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Ho VT; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Jodele S; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Moissev I; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation., Sanchez-Ortega I; European Society for Bone Marrow Transplant., Srivastava A; Department of Haematology, Christian Medical College, Vellore, India., Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan., Carpenter P; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Koreth J; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Kroger N; Division of Hematology, Ohio State University, Columbus, Ohio., Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden., Page K; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin., Popat U; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shaw BE; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain., Soiffer R; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Vasu S; Division of Hematology, Ohio State University, Columbus, Ohio. Electronic address: sumithira.vasu@osumc.edu.
المصدر: Transplantation and cellular therapy [Transplant Cell Ther] 2023 Mar; Vol. 29 (3), pp. 151-163. Date of Electronic Publication: 2022 Nov 25.
نوع المنشور: Practice Guideline; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier Inc., [2021]-
مواضيع طبية MeSH: Thrombotic Microangiopathies*/diagnosis , Thrombotic Microangiopathies*/etiology , Thrombotic Microangiopathies*/pathology , Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*, Humans ; Child ; Prognosis ; Bone Marrow ; Prospective Studies
مستخلص: Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. However, TA-TMA is a clinical diagnosis, and multiple criteria have been proposed without universal application. Although some patients have a self-resolving disease, others progress to multiorgan failure and/or death. Poor prognostic features also are not uniformly accepted. The lack of harmonization of diagnostic and prognostic markers has precluded multi-institutional studies to better understand incidence and outcomes. Even current interventional trials use different criteria, making it challenging to interpret the data. To address this urgent need, the American Society for Transplantation and Cellular Therapy, Center for International Bone Marrow Transplant Research, Asia-Pacific Blood and Marrow Transplantation, and European Society for Blood and Marrow Transplantation nominated representatives for an expert panel tasked with reaching consensus on diagnostic and prognostic criteria. The panel reviewed literature, generated consensus statements regarding diagnostic and prognostic features of TA-TMA using the Delphi method, and identified future directions of investigation. Consensus was reached on 4 key concepts: (1) TA-TMA can be diagnosed using clinical and laboratory criteria or tissue biopsy of kidney or gastrointestinal tissue; however, biopsy is not required; (2) consensus diagnostic criteria are proposed using the modified Jodele criteria with additional definitions of anemia and thrombocytopenia. TA-TMA is diagnosed when ≥4 of the following 7 features occur twice within 14 days: anemia, defined as failure to achieve transfusion independence despite neutrophil engraftment; hemoglobin decline by ≥1 g/dL or new-onset transfusion dependence; thrombocytopenia, defined as failure to achieve platelet engraftment, higher-than-expected transfusion needs, refractory to platelet transfusions, or ≥50% reduction in baseline platelet count after full platelet engraftment; lactate dehydrogenase (LDH) exceeding the upper limit of normal (ULN); schistocytes; hypertension; soluble C5b-9 (sC5b-9) exceeding the ULN; and proteinuria (≥1 mg/mg random urine protein-to-creatinine ratio [rUPCR]); (3) patients with any of the following features are at increased risk of nonrelapse mortality and should be stratified as high-risk TA-TMA: elevated sC5b-9, LDH ≥2 times the ULN, rUPCR ≥1 mg/mg, multiorgan dysfunction, concurrent grade II-IV acute graft-versus-host disease (GVHD), or infection (bacterial or viral); and (4) all allogeneic and pediatric autologous HCT recipients with neuroblastoma should be screened weekly for TA-TMA during the first 100 days post-HCT. Patients diagnosed with TA-TMA should be risk-stratified, and those with high-risk disease should be offered participation in a clinical trial for TA-TMA-directed therapy if available. We propose that these criteria and risk stratification features be used in data registries, prospective studies, and clinical practice across international settings. This harmonization will facilitate the investigation of TA-TMA across populations diverse in race, ethnicity, age, disease indications, and transplantation characteristics. As these criteria are widely used, we expect continued refinement as necessary. Efforts to identify more specific diagnostic and prognostic biomarkers are a top priority of the field. Finally, an investigation of the impact of TA-TMA-directed treatment, particularly in the setting of concurrent highly morbid complications, such as steroid-refractory GVHD and infection, is critically needed.
(Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
References: Eur J Haematol. 2018 Feb;100(2):171-181. (PMID: 29114931)
Am Fam Physician. 2000 Sep 15;62(6):1333-40. (PMID: 11011862)
Blood. 2016 Feb 25;127(8):989-96. (PMID: 26603840)
Int J Lab Hematol. 2021 Dec;43(6):1264-1271. (PMID: 34431220)
Transplantation. 2010 Oct 27;90(8):918-26. (PMID: 20717073)
Bone Marrow Transplant. 2020 Mar;55(3):553-561. (PMID: 31558788)
Blood. 2017 Sep 7;130(10):1259-1266. (PMID: 28705839)
Blood. 2011 Aug 11;118(6):1452-62. (PMID: 21596850)
Blood. 2014 Jul 24;124(4):645-53. (PMID: 24876561)
N Engl J Med. 2017 Mar 23;376(12):1189-1190. (PMID: 28328331)
Biol Blood Marrow Transplant. 2013 Dec;19(12):1683-9. (PMID: 24055655)
Exp Hematol Oncol. 2018 Jun 22;7:14. (PMID: 29977661)
Bone Marrow Transplant. 2021 Oct;56(10):2326-2335. (PMID: 34253879)
J Blood Med. 2016 Sep 02;7:181-6. (PMID: 27621680)
Biol Blood Marrow Transplant. 2015 Nov;21(11):1994-2001. (PMID: 26150023)
Blood Adv. 2018 Oct 23;2(20):2619-2628. (PMID: 30327370)
Bone Marrow Transplant. 2011 May;46(5):682-9. (PMID: 20697372)
Bone Marrow Transplant. 1995 Feb;15(2):247-53. (PMID: 7773214)
J Am Soc Nephrol. 2010 Dec;21(12):2020-7. (PMID: 21051738)
Br J Haematol. 2020 Jun;189(6):1171-1181. (PMID: 32124435)
Biol Blood Marrow Transplant. 2020 Jan;26(1):178-188. (PMID: 31491486)
Biol Blood Marrow Transplant. 2019 Mar;25(3):570-576. (PMID: 30940363)
Clin Transplant. 2018 Sep;32(9):e13371. (PMID: 30080283)
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1719-1732. (PMID: 31694864)
Front Immunol. 2019 Oct 09;10:2339. (PMID: 31649666)
Am J Hematol. 1996 Dec;53(4):213-20. (PMID: 8948657)
Bone Marrow Transplant. 2019 Jul;54(7):1022-1028. (PMID: 30361500)
J Pers Med. 2021 May 25;11(6):. (PMID: 34070379)
Bone Marrow Transplant. 2019 Apr;54(4):540-548. (PMID: 30108323)
Clin Exp Immunol. 2021 Jan;203(1):96-104. (PMID: 32681658)
Hematol Oncol. 2017 Dec;35(4):821-827. (PMID: 27245857)
Int J Hematol. 2019 Nov;110(5):529-532. (PMID: 31586304)
Blood Adv. 2022 Feb 22;6(4):1342-1349. (PMID: 34932790)
Bone Marrow Transplant. 2008 May;41(9):813-20. (PMID: 18209725)
Front Med (Lausanne). 2018 Apr 30;5:122. (PMID: 29761105)
Pediatr Blood Cancer. 2021 Aug;68(8):e29128. (PMID: 34019336)
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025. (PMID: 32943538)
Arch Pathol Lab Med. 2017 Nov;141(11):1558-1566. (PMID: 28795840)
Blood. 1989 May 15;73(7):2018-24. (PMID: 2496776)
Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304. (PMID: 23078784)
Bone Marrow Transplant. 2018 Oct;53(10):1311-1318. (PMID: 29674658)
Immunobiology. 2016 Oct;221(10):1080-90. (PMID: 27371974)
Expert Rev Hematol. 2021 Sep;14(9):831-840. (PMID: 34388057)
Expert Rev Hematol. 2021 Aug;14(8):751-763. (PMID: 34301169)
Blood Adv. 2019 Jun 25;3(12):1881-1890. (PMID: 31221661)
Blood Adv. 2022 Sep 08;:. (PMID: 36075028)
Blood Adv. 2020 Jun 9;4(11):2536-2547. (PMID: 32516415)
Biol Blood Marrow Transplant. 2008 Dec;14(12):1365-72. (PMID: 19041058)
Blood Adv. 2020 Jun 9;4(11):2418-2429. (PMID: 32492158)
Blood. 2018 Jun 21;131(25):2846-2855. (PMID: 29545329)
Hemasphere. 2020 Dec 09;5(1):e487. (PMID: 33324949)
Eur J Immunol. 2018 Oct;48(10):1607-1620. (PMID: 30160302)
Bone Marrow Transplant. 2014 Mar;49(3):403-9. (PMID: 24317123)
Blood Rev. 2015 May;29(3):191-204. (PMID: 25483393)
Thromb Haemost. 2020 Apr;120(4):638-646. (PMID: 32131130)
Bone Marrow Transplant. 2021 Aug;56(8):1805-1817. (PMID: 33875812)
Bone Marrow Transplant. 2014 May;49(5):684-90. (PMID: 24566710)
Transplantation. 2006 Sep 15;82(5):638-44. (PMID: 16969286)
Haematologica. 2017 Dec;102(12):e481-e482. (PMID: 28912175)
N Engl J Med. 2013 Aug 8;369(6):529-39. (PMID: 23924003)
Haematologica. 2021 Aug 01;106(8):2147-2160. (PMID: 32675225)
Front Pediatr. 2019 Apr 09;7:133. (PMID: 31024873)
Blood. 2020 Mar 26;135(13):1049-1057. (PMID: 31932840)
Transplant Cell Ther. 2023 Jan;29(1):45.e1-45.e8. (PMID: 36202334)
Biol Blood Marrow Transplant. 2013 Feb;19(2):202-7. (PMID: 22960385)
Am J Hematol. 2020 Jul 2;:. (PMID: 32618000)
Am J Kidney Dis. 2006 Oct;48(4):564-70. (PMID: 16997052)
Biol Blood Marrow Transplant. 2018 Nov;24(11):2344-2353. (PMID: 29758394)
Transfus Apher Sci. 2002 Aug;27(1):3-12. (PMID: 12201469)
Br J Haematol. 2020 Aug;190(4):508-519. (PMID: 32319084)
Bone Marrow Transplant. 2000 Nov;26(9):1005-9. (PMID: 11100281)
Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7. (PMID: 15983555)
Blood Adv. 2021 Jan 12;5(1):1-11. (PMID: 33570619)
Transplant Cell Ther. 2021 Apr;27(4):308.e1-308.e8. (PMID: 33836868)
Haematologica. 2007 Jan;92(1):95-100. (PMID: 17229640)
معلومات مُعتمدة: R01 HL153723 United States HL NHLBI NIH HHS; UG1 HL109322 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: Complement; Diagnostic criteria; Nonrelapse mortality; Risk stratification; Transplantation-associated thrombotic microangiopathy
تواريخ الأحداث: Date Created: 20221128 Date Completed: 20230303 Latest Revision: 20231129
رمز التحديث: 20231130
مُعرف محوري في PubMed: PMC10119629
DOI: 10.1016/j.jtct.2022.11.015
PMID: 36442770
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-6367
DOI:10.1016/j.jtct.2022.11.015